Future-Proofing the Pharma Customer & Supplier Relationship

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

Continuous adaption
Evolving US tariff/trade policy is but one of the many variables that bio/pharmaceutical companies and their suppliers are facing. Global supply chains are always subject to geopolitical uncertainties, fluctuating economic conditions, and changes in trade and government policies, but the pace of that change has accelerated. Add to that the base challenge of increased product and supply chain complexity in the industry, and the need for bio/pharma companies and their suppliers to adapt is ever more important for supply assurance.

Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer

An executive panel at the DCAT Week program, Future-Proofing the Pharma Customer–Supplier Relationship, will share lessons learned, best practices, and innovative ways on how they are collaborating to enhance supply-chain visibility and resilience, mitigate risk, and optimize supply planning now and for what may lie ahead.

Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb

Participating in the panel of are:  Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer; Emad Abdelsadek, Vice President, Sales, EMEA, BD Biopharma Systems; Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb; and Sara Henneman, Vice President and General Manager, Cell Culture and Cell Therapy, Thermo Fisher Scientific. The panel will be moderated by Vishal Bhandari, Partner, Healthcare & Life Sciences Practice, Americas, Kearney.

The program, Future-Proofing the Pharma Customer–Supplier Relationship, is part of DCAT Week, the premier gathering for companies engaged in the global bio/pharmaceutical business ecosystem, hosted by the Drug, Chemical & Associated Technologies Association (DCAT). DCAT Week will be held March 23–26, 2026, in New York. The program, Future-Proofing the Pharma Customer–Supplier Relationship, will be held on Tuesday March 24, 2026, 11:00 AM–12:00 PM. Further information, including how to register, may be found here. The program is exclusive to DCAT Member Companies.

Recent Feature Articles

Beyond ADCs: Next-Generation Drug Conjugates 

By
Antibody drug conjugates (ADCs) continue to be a strong growth area, but next-generation drug conjugates, encompassing oligonucleotides, peptides, and other small-molecule payloads, are on the rise.

Sandoz Maps Out Ambitious Biosimilars Growth Plan

By
Sandoz has rolled out a plan to increase its biosimilars portfolio to more than 100 biosimilars, including generic GLP-1’s by 2040, increase manufacturing capacity, and more than double its net sales by 2035.

US Government Moves To Counter Ex-US R&D

By
FDA announced plans to increase oversight of clinical trials overseas while proposing a pilot to shorten and remove barriers in the IND process as a means to increase US-based research and counter shifts to ex-US R&D.
Money-pills-flag

The Next Round in US Drug Pricing & Mfg Investments

By
The White House has signed nine new deals for most-favored-nation drug pricing with mid-sized pharma companies, bringing the total of such deals to 26 along with more committments for US-based manufacturing.